BlackRock
ELTX icon

BlackRock’s Elicio Therapeutics ELTX Stock Holding History

BlackRock’s Portfolio ELTX Stock Details ELTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$1.35M Sell
740,259
-25,746
-3% -$71.4K ﹤0.01% 4278
2026
Q2 		$3M Buy
766,005
+715,408
+1,414% +$7.18M ﹤0.01% 4058
2026
Q1 		$541K Buy
50,597
+5,418
+12% +$52.3K ﹤0.01% 4509
2025
Q4 		$360K Buy
45,179
+984
+2% +$8.93K ﹤0.01% 4573
2025
Q3 		$483K Buy
44,195
+638
+1% +$6.46K ﹤0.01% 4463
2025
Q2 		$336K Buy
43,557
+4,234
+11% +$26.3K ﹤0.01% 4538
2025
Q1 		$242K Buy
39,323
+19,512
+98% +$151K ﹤0.01% 4569
2024
Q4 		$101K Buy
19,811
+118
+0.6% +$581 ﹤0.01% 4788
2024
Q3 		$99.1K Buy
19,693
+708
+4% +$3.14K ﹤0.01% 4670
2024
Q2 		$78K Buy
18,985
+18,068
+1,970% +$153K ﹤0.01% 4759
2024
Q1 		$6.97K Hold
917
– – ﹤0.01% 5116
2023
Q4 		$7.65K Buy
+917
New +$5.98K ﹤0.01% 5165
2023
Q2 		– Sell
-5,705
Closed -$33.1K – 5529
2023
Q1 		$33.1K Buy
5,705
+178
+3% +$1.19K ﹤0.01% 5184
2022
Q4 		$44.9K Buy
5,527
+119
+2% +$1.08K ﹤0.01% 5255
2022
Q3 		$50K Sell
5,408
-149
-3% -$1.56K ﹤0.01% 5350
2022
Q2 		$63K Sell
5,557
-95,309
-94% -$1.52M ﹤0.01% 5367
2022
Q1 		$2.14M Sell
100,866
-1,367
-1% -$30.9K ﹤0.01% 4360
2021
Q4 		$2.96M Buy
102,233
+446
+0.4% +$22.6K ﹤0.01% 4238
2021
Q3 		$9.9M Buy
101,787
+73,683
+262% +$7.96M ﹤0.01% 3672
2021
Q2 		$3.66M Sell
28,104
-3,267
-10% -$471K ﹤0.01% 4010
2021
Q1 		$5.67M Buy
+31,371
New +$6.05M ﹤0.01% 3886

Other funds holding ELTX

Shah Capital Management
Shah Capital Management Raleigh, North Carolina $605M AUM 43.69% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.76T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.96T AUM 27.49% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $765B AUM 28.39% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.44T AUM 36.12% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $73.4B AUM 32.8% 1-Year Est. Return
Vanguard Fiduciary Trust
Vanguard Fiduciary Trust Malvern, Pennsylvania $463B AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.21T AUM
Nuveen
Nuveen Charlotte, North Carolina $420B AUM 34.97% 1-Year Est. Return

BlackRock's ELTX Position: Q3 2026 in Review

BlackRock reduced its Elicio Therapeutics (ELTX) stake by 3.4% in Q3 2026, selling an estimated $71.4K and leaving 740,259 shares worth $1.35M. The position accounts for ﹤0.01% of the portfolio, ranked #4278.

BlackRock first reported a position in ELTX in Q1 2021 and has held it in 21 quarters since. The position peaked at $9.9M in Q3 2021. 57 funds tracked by Wall St. Rank hold ELTX as of Q3 2026.

  • BlackRock held 740,259 shares of Elicio Therapeutics worth $1.35M as of Q3 2026.
  • BlackRock sold 25,746 Elicio Therapeutics shares in Q3 2026, an estimated $71.4K.
  • Elicio Therapeutics made up ﹤0.01% of BlackRock's portfolio in Q3 2026, its #4278 holding.
  • BlackRock first reported a position in Elicio Therapeutics in Q1 2021 and has held it in 21 quarters since.
  • BlackRock's Elicio Therapeutics position peaked at $9.9M in Q3 2021.
  • 57 funds tracked by Wall St. Rank held Elicio Therapeutics as of Q3 2026.

Based on BlackRock's 13F filing for Q3 2026, filed 13 Nov 2026.